瘤性和端粒性G-四重复合体:对氨酸-三基联的目标
Nuno M M Moura1, Sofia Guedes1, Diana Salvador2
1LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.
International journal of biological macromolecules
|August 3, 2024
概括
新的氨酸 - 相结合物选择性地稳定癌细胞中的G-四重复合体 (G4). 这些分子显示出结合G4稳定和光动力学疗法 (PDT) 进行癌症治疗的双重方法的潜力.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 富含关氨酸 (G) 的DNA序列在关键的基因组区域 (如端粒和基因促进体) 中形成G四重复 (G4).
- 稳定G4结构提供了一种抑制癌细胞增殖和调节参与亡和衰老的基因表达的策略.
研究的目的:
- 评估新型氨酸-酸结合物作为选择性G4稳定剂的有效性.
- 通过G4稳定和光动力学疗法 (PDT) 探索它们在癌症治疗中的潜在应用.
主要方法:
- 谱光测量分析以确定有效的G4稳定剂.
- 分子动力学模拟用于预测配体-G4结合特异性 (MYC,KRAS).
- 测试Taq聚合酶抑制,细胞毒性,细胞吸收,核定位和单片氧气生成 (1O2) 的测试.
主要成果:
- 两个结合物,P2-PPh3和P3-PPh3,被确定为强大的G4稳定剂.
- 模拟表明,P2-PPh3优先结合MYC,而P3-PPh3的目标是KRAS.
- 这两种配体都表现出Taq聚合酶抑制,选择性细胞毒性对黑色素瘤细胞 (A375,SK-MEL-28) 超过角质细胞,高效的细胞吸收,并在G4相互作用时产生1O2.
结论:
- 合成的氨酸是有效的G4配体,具有治疗癌症的潜力.
- 这些化合物可用于双重治疗策略,结合G4稳定和PDT.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Aromatic Hydrocarbon Cations: Structural Overview
2.8K
Cycloheptatriene is a neutral monocyclic unsaturated hydrocarbon that consists of an odd number of carbon atoms and an intervening sp3 carbon in the ring. The three double bonds in the ring correspond to 6 π electrons, which is a Huckel number, and therefore satisfies the criteria of 4n + 2 π electrons. However, the intervening sp3 carbon disrupts the continuous overlap of p orbitals. As a result, cycloheptatriene is not aromatic.
Removing one hydrogen from the intervening CH2 group...
Removing one hydrogen from the intervening CH2 group...
2.8K


